Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential deals, R&D, commercial and market access strategies.
How it helps
With In Vivo, you’ll benefit from:
How it works
Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service.
Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.
In Vivo
16 Jun 2022
The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information.
In Vivo
02 Mar 2022
Look ahead with our Pharma Outlook 2022 Extract as we discuss what's coming up in the biopharma space.
In Vivo
By Alex Shimmings 05 Jan 2022
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.
In Vivo
By Ashley Yeo 28 Dec 2021
At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.
In Vivo
By Lucie Ellis-Taitt 22 Nov 2021
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.
In Vivo
By Joanne Shorthouse 17 Nov 2021
Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.
In Vivo
By Ben Comer 14 Oct 2021
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
In Vivo
By Ben Comer 07 Sep 2021
Treating opioid addiction successfully requires an individualized approach, and a lot of money. Executives at addiction treatment centers discuss existing barriers in the recovery pathway and the need to destigmatize addiction and mental health disorders.
In Vivo
18 Aug 2021
Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.
In Vivo
By William Masters 16 Aug 2021
Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.
In Vivo
By Mark Ratner 12 Aug 2021
Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.
In Vivo
27 May 2021
Gain insights into managing unexpected events, effectively communicating change, executing crisis management plans, and more. Industry experts share their insights into innovative ways to integrate teams after M&A, manage D&I initiatives, and build strong leadership for a changing workforce.
Topic Leadership
In Vivo, Pink Sheet
13 May 2021
The COVID-19 pandemic has brought about significant manufacturing and distribution challenges and opportunities for Pharma. Seize new opportunities and avoid risk with the strategic commercial and regulatory intelligence you need to stay competitive by subscribing to Pink Sheet and In Vivo.
Topic Strategy
In Vivo
By Alex Shimmings 20 Apr 2021
A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.
In Vivo
By William Masters 13 Apr 2021
As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.
In Vivo
27 Jun 2022
In Vivo
27 Jun 2022
In Vivo
27 Jun 2022
In Vivo
22 Jun 2022
In Vivo
22 Jun 2022
In Vivo
22 Jun 2022
In Vivo
22 Jun 2022
In Vivo
21 Jun 2022
In Vivo
21 Jun 2022
In Vivo
21 Jun 2022
In Vivo
21 Jun 2022
In Vivo
15 Jun 2022
In Vivo
15 Jun 2022
In Vivo
15 Jun 2022
In Vivo
14 Jun 2022
USA
William specializes in
42+ years of experience
Washington DC, USA
Cathy specializes in
41+ years of experience
Washington DC, USA
Denise specializes in
40+ years of experience
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: